Dexmedetomidine on Tourniquet Induced -Systemic Effects
Status:
Completed
Trial end date:
2020-03-05
Target enrollment:
Participant gender:
Summary
Eighty patients were randomly assigned to either control (CON) or dexmedetomidine (DEX)
group. DEX group received a loading dose of 0.5 µg/ kg of intravenous dexmedetomidine over 10
minutes, followed by a continuous infusion of 0.5 µg/kg/h until completion of the surgery.
CON group received the same calculated volume of normal saline. Pain outcomes, metabolic and
coagulative changes after tourniquet application, and after tourniquet release were
investigated.